Program
JMT106
A development code. Also written as “JMT106 Injection”.
Its studies are mostly in Carcinoma, Hepatocellular, led by CSPC Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Group | 11 open or running | phase 1since Aug 26, 2025 | Aug 26, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 26, 2025First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT07275073 · 200 planned · China
Ahead
- Nov 5, 2026Primary completion: phase 1 study in Carcinoma, HepatocellularNCT07275073
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07275073Carcinoma, Hepatocellular · China | 1 | Recruiting | Nov 5, 2026 | 200 |
How it is read
Names in the registry
- “JMT106 Injection”, 1 entry
Codes read as this program: JMT106.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.